Opportunity Information: Apply for PA 10 080
Apply for PA 10 080
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Image Guided Cancer Interventions (STTR R41/R42)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Jan 8, 2010 and posted on Jan 7, 2010.
- Applicants must submit their applications by Jan 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $100,000.00 in funding.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Image Guided Cancer Interventions (STTR R41/R42) funding opportunity (PA 10 080) is a National Cancer Institute (NCI) grant program under the National Institutes of Health that focuses on moving practical, clinically useful image guided intervention (IGI) technologies for cancer toward real-world use. The central aim is to support small businesses that are building systems that do more than just generate images; the program is looking for integrated solutions that combine cancer imaging with monitoring and therapy so clinicians can plan, target, and assess an intervention in a more precise and informed way. In other words, the emphasis is on complete intervention systems that help guide cancer treatment and evaluate what is happening during and after the procedure, rather than isolated components that are not designed to work together in a clinical workflow.
A major theme of the announcement is development plus clinical validation. Applicants are encouraged not only to design and optimize fully integrated IGI platforms, but also to validate those platforms through clinical evaluations. The FOA explicitly points toward the kind of development work that makes a technology realistic for adoption, such as building and refining an end-to-end system that can be tested in patients, and generating evidence that the integrated approach performs as intended in clinical settings. The opportunity also anticipates that meaningful clinical validation may require more than one unit of hardware or more than one prototype system, especially for multisite clinical evaluations. Because of that, the FOA highlights the development of multiple prototype integrated IGI systems when needed so the technology can be evaluated at more than one clinical center under comparable conditions.
The program is also structured to push collaboration, which is a key feature of the STTR mechanism. It encourages partnerships among small businesses, larger industry partners, and academic clinical centers, as well as small business joint ventures, with the idea that IGI systems typically require a mix of engineering, imaging science, software, therapy delivery expertise, regulatory and quality considerations, and real clinical access. By promoting these relationships, NCI is signaling that strong applications will often include credible clinical collaborators and a development plan that fits clinical realities, including how the system will be used in procedure rooms, how it will integrate with existing tools, and how performance will be measured in patient-facing studies.
On the funding and award structure, this opportunity uses the STTR grant mechanisms R41/R42, meaning it supports Phase I (early feasibility and proof-of-concept), Phase II (expanded development and validation), and Fast Track applications (a streamlined path that covers Phase I and Phase II in a single application when the project is ready for that). It runs in parallel with a separate, companion FOA of the same scientific scope that uses the SBIR mechanisms (R43/R44), identified as PA 10 079. This parallel structure gives small businesses a choice of the STTR path (which requires a formal small business and research institution partnership) versus the SBIR path, depending on how the team and workshare are set up.
Eligibility is limited to small businesses, and the announcement indicates there is no cost sharing or matching requirement. The award ceiling listed in the source data is $100,000. The FOA notes that the number of awards and total dollars ultimately committed depend on available funds and on how many high-quality, meritorious applications are received, so there is no guaranteed award count. Programmatically, it sits under CFDA numbers 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research), reflecting that image guided interventions often span both diagnostic guidance and therapy delivery.
In terms of timing and status, the opportunity was posted in early January 2010, with an original and current closing date of January 7, 2013, and an archive date of February 7, 2013, meaning it is no longer active as a live solicitation. For full historical details, NCI pointed applicants to the archived NIH Grants Guide listing (PA 10 080) and provided NIH Office of Extramural Research (OER) webmaster contact information for access or linking issues.
Frequently Asked Questions (FAQs): Image Guided Cancer Interventions (STTR R41/R42) - PA 10 080
1) What is the Image Guided Cancer Interventions (STTR R41/R42) opportunity (PA 10 080)?
PA 10 080 is a National Cancer Institute (NCI) funding opportunity under the National Institutes of Health (NIH) that supports small businesses developing image guided intervention (IGI) technologies for cancer, with an emphasis on moving practical, clinically useful intervention systems toward real-world use.
2) What is the main goal of this NCI program?
The central aim is to help small businesses develop clinically useful, integrated IGI systems that combine imaging with monitoring and therapy so clinicians can plan, target, and assess cancer interventions more precisely during and after procedures.
3) What kinds of technologies or solutions is the FOA looking for?
The announcement emphasizes complete intervention systems, not just standalone imaging devices or isolated components. The program is looking for integrated solutions that fit into a clinical workflow and help guide treatment and evaluate what is happening during and after the intervention.
4) Does the program fund imaging-only tools?
Based on the description provided, the emphasis is on systems that do more than generate images. The focus is on integration of imaging with monitoring and therapy to support planning, targeting, and assessment of an intervention.
5) Is clinical validation expected as part of the project?
Yes. A major theme is development plus clinical validation. Applicants are encouraged to not only design and optimize fully integrated IGI platforms, but also validate them through clinical evaluations and generate evidence that the integrated approach performs as intended in clinical settings.
6) Why does the FOA highlight development of multiple prototype systems?
The FOA anticipates that meaningful clinical validation may require more than one unit of hardware or more than one prototype system, especially for multisite clinical evaluations. Developing multiple comparable prototype integrated systems can enable evaluation at more than one clinical center under similar conditions.
7) What kinds of collaborations does this opportunity encourage?
This opportunity encourages partnerships among small businesses, larger industry partners, and academic clinical centers, as well as small business joint ventures. The goal is to bring together the mix of engineering, imaging science, software, therapy delivery expertise, regulatory and quality considerations, and clinical access often needed for IGI systems.
8) Why is collaboration emphasized in this opportunity?
The funding mechanism is STTR, which is structured to push collaboration. NCI signals that strong applications will often include credible clinical collaborators and a development plan that fits clinical realities, including how the system will be used in procedure rooms, how it integrates with existing tools, and how performance will be measured in patient-facing studies.
9) What grant mechanisms are used in this opportunity?
The opportunity uses the STTR grant mechanisms R41/R42. It supports Phase I (early feasibility and proof-of-concept), Phase II (expanded development and validation), and Fast Track applications (a single application covering Phase I and Phase II when the project is ready).
10) What is the difference between Phase I, Phase II, and Fast Track under this FOA?
Phase I supports early feasibility and proof-of-concept work. Phase II supports expanded development and validation. Fast Track is an option that combines Phase I and Phase II into one streamlined application when a project is ready to propose both phases together.
11) Is there a related SBIR funding opportunity for the same topic?
Yes. This STTR FOA (PA 10 080) runs in parallel with a companion FOA of the same scientific scope that uses the SBIR mechanisms R43/R44, identified as PA 10 079.
12) How does a small business choose between the STTR and SBIR paths mentioned?
The parallel structure is described as giving small businesses a choice between the STTR path (which requires a formal small business and research institution partnership) and the SBIR path, depending on how the team and workshare are set up.
13) Who is eligible to apply?
Eligibility is limited to small businesses.
14) Is cost sharing or matching required?
No. The announcement states there is no cost sharing or matching requirement.
15) What is the award ceiling listed for this opportunity?
The award ceiling listed in the source data is $100,000.
16) How many awards will be made?
The FOA indicates the number of awards and the total dollars committed depend on available funds and on the number of high-quality, meritorious applications received. There is no guaranteed award count.
17) What CFDA numbers are associated with this program?
This opportunity is listed under CFDA 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research), reflecting that image guided interventions can span both diagnostic guidance and therapy delivery.
18) When was this opportunity posted, and what were the key dates?
The opportunity was posted in early January 2010. The original and current closing date listed is January 7, 2013. The archive date is February 7, 2013.
19) Is PA 10 080 currently active?
No. With a closing date of January 7, 2013 and an archive date of February 7, 2013, it is no longer active as a live solicitation.
20) Where were applicants directed to find full historical details?
NCI directed applicants to the archived NIH Grants Guide listing for PA 10 080 for full historical details.
21) Who was listed as a contact for access or linking issues related to the posting?
The opportunity provided the NIH Office of Extramural Research (OER) webmaster contact information for access or linking issues.
Browse more opportunities from the same category: Education Health
Next opportunity: Novel Tools for Investigating Brain derived GPCRs in Mental Health Research (SBIR R43/R44)
Previous opportunity: Image Guided Cancer Interventions (SBIR R43/R44)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 10 080
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 10 080) also looked into and applied for these:
| Funding Opportunity |
|---|
| Shared Instrumentation Grant Program (S10) Apply for PAR 10 082 Funding Number: PAR 10 082 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Systems Biology, HIV/AIDS, and Substance Abuse (R01) Apply for RFA DA 10 014 Funding Number: RFA DA 10 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Pre Application for the 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (X02) Apply for PAR 10 095 Funding Number: PAR 10 095 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1) Apply for RFA DA 10 013 Funding Number: RFA DA 10 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medications Development for Substance Related Disorders (R01) Apply for RFA DA 10 018 Funding Number: RFA DA 10 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Deep Sequencing and Analysis of Pharmacogenomic Regions Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01) Apply for RFA DA 10 019 Funding Number: RFA DA 10 019 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Institutional Clinical and Translational Science Award (U54) Apply for RFA RM 10 001 Funding Number: RFA RM 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R01) Apply for PAS 10 097 Funding Number: PAS 10 097 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R34) Apply for PAS 10 098 Funding Number: PAS 10 098 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R01) Apply for RFA NR 10 001 Funding Number: RFA NR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R21) Apply for RFA NR 10 002 Funding Number: RFA NR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) Apply for PA 10 108 Funding Number: PA 10 108 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Comprehensive Partnerships to Reduce Cancer Health Disparities (Limited Competition U54) Apply for RFA CA 10 503 Funding Number: RFA CA 10 503 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R21) Apply for RFA NR 10 007 Funding Number: RFA NR 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R01) Apply for RFA NR 10 006 Funding Number: RFA NR 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Common Pathogenetic Mechanisms of Lung Cancer and COPD (R01) Apply for RFA HL 11 002 Funding Number: RFA HL 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Clinical Trials in Drug Abuse (Collaborative R01) Apply for PAR 10 099 Funding Number: PAR 10 099 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Strategic Partnering to Evaluate Cancer Signatures SPECS II (U01) Apply for PAR 10 126 Funding Number: PAR 10 126 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (Competitive Revision R01) Apply for RFA NR 10 005 Funding Number: RFA NR 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (R01) Apply for RFA NR 10 004 Funding Number: RFA NR 10 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 10 080", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.